Associate Vice President - HEOR - Oncology

At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to our communities through philanthropy and volunteerism. We give our best effort to our work, and we put people first. We’re looking for people who are determined to make life better for people around the world.

Organization Overview  ​

At Lilly, we serve an extraordinary purpose. We make a difference for people around the globe by discovering, developing and delivering medicines that help them live longer, healthier, more active lives. Not only do we deliver breakthrough medications, but you also can count on us to develop creative solutions to support communities through philanthropy and volunteerism. 

Role Overview

This role is the accountable leader for global Health Economics and Outcomes Research (HEOR) strategy and execution within the Oncology Business Unit. The M4 owns the HEOR program end-to-end across all OBU assets, partnering with tumor teams, clinical development, market access, commercial, and payer-facing functions to ensure a rigorous, strategically aligned evidence base that supports the clinical and economic value of Lilly oncology medicines. This is a leadership role where the Global Medical Affairs HEOR Lead is expected to make decisions, anticipate risks, drive team performance, and deliver results with urgency.

Leadership Expectations

The M4 is expected to demonstrate the following leadership behaviors as a baseline requirement of the role:

• Scientific & Methodological Command: Maintain comprehensive, continuously updated mastery of HEOR methodologies — including patient-reported outcomes (PROs), real-world evidence (RWE) design, cost-effectiveness modeling, burden of illness research, and comparative effectiveness — as applied to oncology. The M4 must be the definitive HEOR authority within the OBU and credible to payers, HTA bodies, and scientific peers.
• Program Ownership: Own the HEOR evidence portfolio as a business priority. Anticipate gaps in the evidence base, identify issues before they surface, and drive proactive solutions across tumor teams.
• Accountability & Decision-Making: Be accountable for program outcomes by making decisions and clearly identifying HEOR priorities across a complex, multi-asset portfolio.
• Strategic Thinking: Connect scientific, economic, and payer landscape insights to shape the HEOR strategy. Lead a strong HEOR point of view with cross-functional and affiliate leaders.
• Urgency & Delivery: Operate with a bias toward action. Drive timelines, remove obstacles, and deliver HEOR evidence commitments aligned to asset milestones and payer access needs.
• Cross-Functional Partnership: Effectively partner with tumor leads, GPLs, clinical development, market access, commercial, and affiliate leaders to integrate HEOR evidence into a single, cohesive asset strategy.
• People Leadership: Lead, coach, and develop the HEOR team, setting clear expectations and holding team members accountable for performance, impact, and professional growth.
• Team Culture: Create a collaborative, high-performance, inclusive team culture where candid feedback, coaching, and peer learning are the norm.

HEOR Strategy & Execution

• Own the global HEOR strategy across the OBU portfolio, from early pipeline through lifecycle management. Ensure evidence generation plans are prospectively integrated into clinical development and medical affairs planning while appropriately prioritizing asset risk and OBU strategy.
• Develop and maintain a portfolio-level HEOR evidence roadmap that identifies data gaps, prioritizes studies by asset and indication, and aligns to value demonstration milestones.
• Facilitate the design, execution, and oversight of HEOR studies including PRO endpoint strategy, health utility studies, indirect treatment comparisons (ITCs), cost-effectiveness models, real-world evidence studies, and burden of illness analyses.
• Own the integrated PRO and patient experience strategy for OBU assets — including endpoint selection, instrument validation, data collection, and communication of PRO findings in publications and HTA submissions.
• Oversee real-world evidence strategy and execution in partnership with tumor teams and data science resources; ensure RWE studies are appropriately designed to address payer and regulatory needs.
• Provide strategic HEOR input into clinical trial design in collaboration with clinical development, including PRO endpoint selection, data collection burden, and protocol review.
• Own the HEOR-related scientific communication strategy: manuscripts, abstracts, posters, HTA dossier support, and value frameworks. Ensure timely, high-quality evidence dissemination, including pull through strategy (field, omnichannel, etc).
• Manage the HEOR budget and resource allocation across the team. Operate with discipline and transparency.
• Maintain fluency in the global HTA landscape including NICE, G-BA, HAS, CADTH, and other key bodies; proactively advise tumor teams and GPLs on HTA implications for evidence generation strategy.
• Request, plan, and steward HEOR budget and deliverables.

External Engagement and Scientific Communication

• Engage strategically with HEOR thought leaders, outcomes researchers, academic institutions, and payer/HTA stakeholders to advance the evidence base and scientific credibility of OBU assets.
• Lead the HEOR external engagement strategy in alignment with tumor teams, market access, and affiliate functions.
• Oversee HEOR-related congress strategy, including ISPOR, ASCO, ESMO, ASH, and other relevant venues — including study presentations, podium sessions, and advisory boards focused on value evidence.
• Support payer advisory boards and value evidence review forums in partnership with market access and commercial teams.
• Build and maintain a network of HEOR academic collaborators and external experts to strengthen IIR/ERC pipeline and publication strategy.

Cross-Functional & Regional Partnership

• Partner with the Market Access and COO/PM teams to ensure HEOR deliverables are aligned to reimbursement timelines and access strategy.
• Provide HEOR input to the US Medical team and affiliate medical affairs functions to support field-based evidence dissemination and payer engagement.
• Be the voice of global HEOR to the regions; bring affiliate, payer, and HTA insights back to inform the portfolio evidence strategy.
• Provide leadership to external HEOR partners, CROs, and academic collaborators to deliver on global objectives.
• Drive consistency and scientific rigor across all HEOR deliverables in alignment with medical and commercial strategy.

Basic Qualifications

• Advanced doctoral degree required (PhD, PharmD, MD, or DO). PhD in health economics, outcomes research, epidemiology, biostatistics, health services research, or a related quantitative discipline is strongly preferred.
• U.S.-trained physicians must have achieved board eligibility or certification.
• Foreign medical graduates in U.S.-based jobs who are not U.S. board eligible or certified may be hired at the discretion of the Chief Medical Officer.
• Non-U.S.-trained physicians must have completed education and training at a medical school meeting LCME requirements.

Additional Preferences

Non-negotiable (must demonstrate in interview process):

• Demonstrated strategic leadership in HEOR, with evidence of portfolio-level program ownership, proactive evidence gap identification, and delivery under ambiguity.
• Deep expertise in HEOR methodologies — including economic modeling, PROs, RWE design, and HTAs — with demonstrated ability to apply these rigorously in oncology contexts.
• Track record of holding teams accountable, coaching for performance, and making difficult decisions.
• Ability to influence cross-functionally and create urgency without positional authority.
• Collaborate with enterprise-wide HEOR leaders to ensure policies, procedures, and operations are executed and shaped to drive impact and eliminate inefficiencies.
• Strong communication skills — able to translate complex HEOR evidence for executive, commercial, payer, and clinical audiences.
• Depth of understanding of the global HTA and payer landscape and its implications for oncology evidence strategy.

Strongly preferred:

• HEOR experience in oncology, including experience supporting global market access submissions or HTA dossiers.
• Experience with PRO endpoint strategy, instrument validation, and regulatory/HTA guidance on patient-reported outcomes.
• Demonstrated ability to balance scientific rigor with business priorities and reimbursement timelines.
• Fluent in English, verbal and written.

Lilly is dedicated to helping individuals with disabilities to actively engage in the workforce, ensuring equal opportunities when vying for positions. If you require accommodation to submit a resume for a position at Lilly, please complete the accommodation request form (https://careers.lilly.com/us/en/workplace-accommodation) for further assistance. Please note this is for individuals to request an accommodation as part of the application process and any other correspondence will not receive a response.

Lilly is proud to be an EEO Employer and does not discriminate on the basis of age, race, color, religion, gender identity, sex, gender expression, sexual orientation, genetic information, ancestry, national origin, protected veteran status, disability, or any other legally protected status.

Our employee resource groups (ERGs) offer strong support networks for their members and are open to all employees. Our current groups include: Africa, Middle East, Central Asia Network, Black Employees at Lilly, Chinese Culture Network, Japanese International Leadership Network (JILN), Lilly India Network, Organization of Latinx at Lilly (OLA), PRIDE (LGBTQ+ Allies), Veterans Leadership Network (VLN), Women’s Initiative for Leading at Lilly (WILL), enAble (for people with disabilities). Learn more about all of our groups.

Actual compensation will depend on a candidate’s education, experience, skills, and geographic location.  The anticipated wage for this position is

$243,000 - $431,200

Full-time equivalent employees also will be eligible for a company bonus (depending, in part, on company and individual performance). In addition, Lilly offers a comprehensive benefit program to eligible employees, including eligibility to participate in a company-sponsored 401(k); pension; vacation benefits; eligibility for medical, dental, vision and prescription drug benefits; flexible benefits (e.g., healthcare and/or dependent day care flexible spending accounts); life insurance and death benefits; certain time off and leave of absence benefits; and well-being benefits (e.g., employee assistance program, fitness benefits, and employee clubs and activities).Lilly reserves the right to amend, modify, or terminate its compensation and benefit programs in its sole discretion and Lilly’s compensation practices and guidelines will apply regarding the details of any promotion or transfer of Lilly employees.

#WeAreLilly